Shu YQ - Search Results

1

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.

Zhou Q, Xu CR, Cheng Y, Liu YP, Chen GY, Cui JW, Yang N, Song Y, Li XL, Lu S, Zhou JY, Ma ZY, Yu SY, Huang C, Shu YQ, Wang Z, Yang JJ, Tu HY, Zhong WZ, Wu YL. Zhou Q, et al. Among authors: shu yq. Cancer Cell. 2021 Sep 13;39(9):1279-1291.e3. doi: 10.1016/j.ccell.2021.07.005. Epub 2021 Aug 12. Cancer Cell. 2021. PMID: 34388377 Free article. Clinical Trial.

2

[Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study].

Hu B, Yu JR, Wen ZZ, Shu YQ, Wang BC, Yin HR, Chen L, Bai YX, Liang J, Chen L, Cheng Y, Shen L, Zhou Y, Zhang HG, Li J, Wan DS, Chen S, Jia TZ, Jin ML. Hu B, et al. Among authors: shu yq. Zhonghua Zhong Liu Za Zhi. 2008 Dec;30(12):940-3. Zhonghua Zhong Liu Za Zhi. 2008. PMID: 19173999 Clinical Trial. Chinese.

3

Genetic variants in one-carbon metabolism-related genes contribute to NSCLC prognosis in a Chinese population.

Jin G, Huang J, Hu Z, Dai J, Tang R, Chen Y, Xu L, Huang X, Shu Y, Shen H. Jin G, et al. Cancer. 2010 Dec 15;116(24):5700-9. doi: 10.1002/cncr.25301. Epub 2010 Aug 24. Cancer. 2010. PMID: 20737570 Free article.

4

Restoration of gefitinib efficacy following chemotherapy in a patient with metastatic non-small cell lung cancer.

Li XD, Geng YT, Wu CP, Shen H, Sun J, Shu YQ, Yin YM. Li XD, et al. Among authors: shu yq. Onkologie. 2010;33(8-9):466-9. doi: 10.1159/000319109. Epub 2010 Jul 27. Onkologie. 2010. PMID: 20838064

5

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer.

Yin YM, Geng YT, Shao YF, Hu XL, Li W, Shu YQ, Wang ZX. Yin YM, et al. Among authors: shu yq. J Exp Clin Cancer Res. 2010 Sep 15;29(1):126. doi: 10.1186/1756-9966-29-126. J Exp Clin Cancer Res. 2010. PMID: 20843324 Free PMC article.

6

The regimen of gemcitabine and cisplatin combined with radio frequency hyperthermia for advanced non-small cell lung cancer: a phase II study.

Shen H, Li XD, Wu CP, Yin YM, Wang RS, Shu YQ. Shen H, et al. Among authors: shu yq. Int J Hyperthermia. 2011;27(1):27-32. doi: 10.3109/02656736.2010.500645. Epub 2010 Sep 21. Int J Hyperthermia. 2011. PMID: 20858088 Free article. Clinical Trial.

7

The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data.

Liu L, Shao X, Gao W, Bai J, Wang R, Huang P, Yin Y, Liu P, Shu Y. Liu L, et al. J Thorac Oncol. 2010 Dec;5(12):1922-32. doi: 10.1097/jto.0b013e3181f26266. J Thorac Oncol. 2010. PMID: 21155183 Free article.

8

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer.

Guo R, Chen X, Wang T, Zhang Z, Sun J, Shu Y. Guo R, et al. BMC Cancer. 2011 Mar 2;11:90. doi: 10.1186/1471-2407-11-90. BMC Cancer. 2011. PMID: 21366910 Free PMC article.

9

Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer.

Wei J, Gao W, Zhu CJ, Liu YQ, Mei Z, Cheng T, Shu YQ. Wei J, et al. Among authors: shu yq. Chin J Cancer. 2011 Jun;30(6):407-14. doi: 10.5732/cjc.010.10522. Chin J Cancer. 2011. PMID: 21627863 Free PMC article.

10

Phase II study of weekly irinotecan plus cisplatin in patients with previously untreated extensive-stage extrapulmonary small cell carcinoma.

Jin S, Wang T, Chen X, Xu B, Sun J, Guo R, Shu Y. Jin S, et al. Onkologie. 2011;34(7):378-81. doi: 10.1159/000329609. Epub 2011 Jun 24. Onkologie. 2011. PMID: 21734424 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

458 results

Search Page

Filters